Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma

Transgene

Status and phase

Completed

Phase 2

Conditions

Lymphoma, B-Cell

Treatments

Genetic: Adenovirus Interferon gamma

Study type

Interventional

Funder types

Industry

Identifiers

NCT00394693

TG1042.06

Details and patient eligibility

About

The primary objective of this study is to evaluate the efficacy of a four-month dosing period of intra-lesional injection of TG1042 in patients with relapsing CBCL.

Patients will receive intra-tumoral injections of an adenoviral vector construct containing the human interferon gamma gene (TG1042), in an attempt to enhance immune responses with anti-tumor activity. This local administration induces tumour cell killing at the injected tumour sites.

Enrollment

13 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must satisfy all the following criteria for entry into the protocol:

Primary CBCL including (according to WHO/EORTC classification 2005) :

Primary cutaneous marginal zone B-cell lymphoma
Primary cutaneous follicle center B-cell lymphoma
Primary cutaneous diffuse large B-cell other than leg type
- Histologically consistent with primary CBCL.
- Relapse or active disease after radiotherapy or other adequate therapy if radiotherapy was contra-indicated (chemotherapy, surgical excision, interferonα, rituximab).
- Performance status of 0, 1 on the Eastern Cooperative Oncology Group (ECOG) scale (See Appendix E).
- Minimum Life Expectancy > 3 months.
- Adequate blood count: hemoglobin >= 10.0 g/dL; White Blood Count (WBC) >= 3.0 x 109/L; and platelet count >= 75 x 109/L.
- Adequate hepatic function: bilirubin =< 1.5 times the upper limit of normal and serum transaminase (SGOT and SGPT)=< 2.5 times the upper limit of normal.
- Adequate renal function: creatinine =< 1.5 times the upper limit of normal.
- Written informed consent from patient.

Exclusion criteria

Patients will be excluded from the study for any of the following reasons:

Primary cutaneous diffuse large B-cell lymphoma, leg type.
Primary cutaneous intravascular large B-cell lymphoma.
Extracutaneous involvement (sign of B-cell lymphoma on thoraco-abdominal CT scan and/or PET scan and/or on bone marrow biopsy).
No histologic documentation of CBCL.
History of known Human Immuno-deficiency Virus, Human Hepatitis B or C positive serology or other active systemic infections.
Serious uncontrolled, concomitant medical disorders.
Concomitant therapy for CBCL: surgical resection, radiotherapy, corticosteroid, chemotherapy, rituximab...(not limited listing)
Major surgery in previous 4 weeks preceding the 1st injection.
Pregnancy at study entry or who become pregnant during the study or women who are breast feeding.
Males and females of reproductive potential who refuse to use adequate protection against pregnancy (intra-uterine device, hormonal contraception or diaphragm/condom and spermicide) during the conduct of the study and for three months after the last injection.
Participation in another experimental protocol during the study period and within 4 weeks prior to the first injection.
Patient previously included in this study.
Non compliance with the study.